unknown

An in-vitro Study on Reversing the Multidrug Resistance of Ovarioma by siRNA Regulated by hTERT Promoter

Abstract

背景与目的:卵巢癌死亡率居妇科恶性肿瘤之首,化学药物治疗(化疗)耐药是造成患者总体预后不良的主要原因之一。mdr1基因及其表达产物P-gP被认为是引起多药耐药的主要原因。siRNA沉默技术是近年来兴起的一种新型的基因阻断技术。成功应用RNA干扰沉默mdr1逆转耐药采用RNA聚合酶Ⅲ启动子(H1,U6)表达经典的发夹结构RNA,缺乏组织细胞靶向性。本研究选择了具有组织特异性的hTERT启动子介导靶向mdr1的shRNA的表达,以期特异抑制mdr1表达从而逆转卵巢癌多药耐药。 方法: 1.通过利用Therom在线设计软件获得2个可识别不同位点的候选siRNA靶点序列,引用1个他人设计siRNA...Backgrouds & Objectives Ovarian carcinoma takes the first place in the mortality of all the gynecologic malignant tumors, one of the major reasons of the bad prognostics is the resistance of chemical therapy. The gene of mdr1 and its production P-gP are considered as the major factor of MDR. siRNA is a new technology to block gene expressing that has come up in recent years. Evidence has shown th...学位:医学硕士院系专业:医学院临床医学系_外科学学号:2452007115253

    Similar works